to separate tissue absorption from scattering properties in diffuse optical imaging; these were reviewed by Gibson et al. 1 Since these methods deliver, in particular, the concentrations of oxy-and deoxyhaemoglobin, NIR optical imaging facilitates characterisation of diseases connected with changes in the vasculature or the local metabolic state such as inflammations, the development of cancer, or vascular obliterations. Accordingly, NIR imaging has been applied, for example, to the detection of breast cancer, [2] [3] [4] [5] to functional brain imaging [6] [7] [8] and to the characterisation of stroke disease. [9] [10] [11] Furthermore, optical tomography and spectroscopy have been employed to the detection of rheumatoid arthritis in finger joints. 12, 13 Together with the development of experimental methods for NIR imaging, pharmaceutical research began to pursue the development of fluorescent contrast agents for diffuse optical imaging to improve the detection of diseases. In the 1990s, several dyes with near infrared absorption and fluorescence were synthesised with the aim of exploiting the neoangiogenesis in carcinomas and other diseases as contrast mechanisms. 14, 15 The basic structure of these dyes was derived from the contrast agent indocyanine green (ICG), which is a well-tolerated drug for investigations on humans. The indocyanine derivatives were successfully tested on small animals with near-surface lesions using fluorescence imaging. As reviewed by Bremer et al. 16 cyanine dyes have also been conjugated to specific ligands to obtain targeting probes for NIR molecular imaging. Generally, optical molecular imaging is expected to improve early detection of diseases. 17 However, molecular probes for fluorescence imaging have not yet been approved for in vivo application on humans. Furthermore, only one of the unspecific indocyanine derivatives developed, called omocyanine (or omocianine), was applied in investigations on humans. 18, 19 Therefore, the interest of several research groups developing methods for diffuse optical imaging of diseases in humans has focused on ICG as a contrast agent. Other dyes for optical imaging such as methylene blue, patent blue, or fluorescein have shorter absorption wavelengths making them less suited for imaging of deeper tissue structures. In this review, we discuss recent results on the application of ICG for the detection and characterisation of diseases by diffuse optical imaging with a focus on breast cancer, stroke and rheumatoid arthritis. We give a short overview of the related properties of ICG, present selected experimental techniques, discuss absorption and fluorescence measurements and compare the results with ICG to optical imaging based on the intrinsic tissue properties. Finally, we summarise the advantages which make ICG an interesting contrast agent in present biomedical research.
The contrast agent indocyanine green
Indocyanine green is a NIR absorbing and fluorescent dye with a molecular weight of 775 g mol −1 . A detailed overview on the basic properties of ICG can be found in the paper by Desmettre et al. 20 ICG has both hydrophilic and lipophilic properties. After intravenous injection, the dye molecules bind immediately to plasma proteins. 20 Therefore, ICG is often called a bloodpool agent. Binding sites are high-density and low-density lipoproteins as well as albumin at high dye concentrations. 21 Hereby, binding to albumin is weak compared to the stronger binding to lipoproteins. 22, 23 The absorption spectrum of the dye depends on the solvent and the dye concentration. In aqueous solution, the absorption maximum is at a wavelength of about 785 nm for concentrations below 5 µmol L −1 . For higher concentrations, ICG tends to form aggregates and an additional absorption peak arises at a wavelength of 690 nm. 24 If the aqueous solution additionally contains serum albumin, then the absorption maximum is around 805 nm and aggregation is reduced. 24 For intravenous injection, ICG has to be dissolved in water. The fluorescence emission in aqueous solution peaks at about 810 nm to 820 nm. 25, 26 After intravenous injection, the fluorescence maximum shifts immediately towards 830 nm. 25, 27 ICG bound to serum albumin in water shows a bi-exponential fluorescence decay with lifetimes of 615 ps and 190 ps. 28 Published values of ICG fluorescence lifetime in pure water range between 166 ps and 170 ps. 29, 30 The quantum yield of ICG in the physiological environment and in water is about 3% and 1%, respectively. 14 ICG has a very low toxicity. 31 In humans with normal liver function the dye is washed out from the blood usually within 5-10 min. From the liver ICG is secreted into the bile. Several pharmacokinetic studies on humans have shown a bi-exponential decay of the ICG blood concentration with a short half-life of about 4 min and a long half-life of about 1 h for low concentrations. 26, 32, 33 Meijer et al. 32 reported that the long half-life increases with increasing doses of ICG. For a dose of dye of 0.5 mg kg −1 body weight they observed a half-life of about 63 min (average of six subjects) whereas for 2 mg kg −1 the half-life was increased to about 89 min (average of four subjects). Investigations of the biliary excretion rate at the highest dose gave hints on nonlinear elimination mechanisms due to saturation effects. 32 Clinical applications of indocyanine green ICG has found various clinical applications. Originally it was used for cardiac output monitoring. [34] [35] [36] Another application is the test of hepatic function, in which the wash-out of the intravenously injected dye from the blood by the liver is recorded by absorption measurements, for example, with a finger clip. 37 In ophthalmology, ICG is used for fluorescence imaging of retinal and choroidal vasculature. 20 Hereby it was observed that ICG diffuses slowly throughout the vessels into the choroidal stroma, despite the strong binding to plasma proteins. 38 All these applications are covered, to a large extent, by commercially available monitoring devices.
In recent years, several studies were reported on the use of ICG as a lymphatic tracer for sentinel lymph node mapping in surgical oncology. As reviewed by Schaafsma et al. 39 and by Polom et al., 40 investigations were performed on breast, skin, gastric, colorectal, anal and lung cancers with promising results. Closely connected to this application of ICG, the dye was used to diagnose lymphoedema intraoperatively. 40 ICG was also applied to assess tumour margins during surgery for patients with hepatobiliary cancer. 39 In reconstructive surgery using free flaps, fluorescence angiography with ICG was successfully employed to visualise blood flow prior and after flap transfer. 39, 40 Optical mammography with indocyanine green
Current status of breast imaging
Breast cancer is one of the most frequent cancer diseases among women, in particular in the industrial countries. The standard screening tool is X-ray mammography which has a sensitivity of about 85% and a specificity of about 60%. 41 In a large number of cases, X-ray mammography cannot reliably distinguish benign from malignant lesions. 42 Moreover, imaging of dense breast tissue remains a problem for this method. 43 Magnetic resonance (MR) breast imaging uses a contrast agent (gadolinium chelates such as Gd-DTPA) to detect lesions. Although the sensitivity is generally higher than in X-ray mammography, estimates of specificity vary greatly. 44, 45 Furthermore, different sonographic methods have been developed to investigate tissue structures and their elasticity and to diagnose malignant tumours. 46, 47 NIR optical spectroscopy of the breast offers the possibility to exploit the increased haemoglobin concentration of carcinomas due to neoangiogenesis as the contrast mechanism. Several clinical studies have confirmed that carcinomas can be detected in this way, however, with a low specificity. 2, 4, 48 There are some hints that high spectral resolution could help to overcome this situation. 49 However, the most promising way to improve detection of breast tumours by optical imaging seems to be the application of a suited contrast agent, in analogy to contrast-enhanced MRI of the breast. In the following, we will review the results obtained so far.
Experimental methods
To image an absorbing and fluorescent contrast agent in breast tissue in vivo, two basic measurement geometries have been applied (Figure 1 ), which correspond to the geometries used for imaging the intrinsic tissue contrast. The first geometry is realised by slab-like soft compression of the breast between two parallel plates. These plates are typically equipped with optical fibres for illumination and light detection, either in a fixed configuration or mounted on translation stages to allow for scanning the breast [ Figure  1 (a)]. Data can be acquired in a simple tandem configuration, or in a multi-projection configuration suitable for threedimensional (3D) reconstruction of the distribution of the contrast agent in the tissue. Generally, light detection is possible by photomultipliers or photodiodes using either time-resolved, frequency-domain or continuous wave (CW) techniques. Alternatively, sensitive CCD cameras can be used [ Figure 1(b) ]. In the case of fluorescence measurements, appropriate spectral filters have to be integrated into the set-up. The second basic geometry is the freely pending breast. Illumination and detection fibres are mounted either on ring holders [ Figure 1 (c)] or in a full 3D configuration [ Figure 1(d) ]. Accordingly, optical images are obtained by 2D or 3D reconstruction methods. Coupling between fibres and tissue is realised by direct contact or by a scattering liquid acting as a matching fluid [ Figure 1(d) ]. In general, the circular geometry is suited to tomographic reconstruction, since the tissue can be trans-illuminated in all directions from multiple source positions. In the slab-like geometry, projection directions are limited to (oblique) transmission and reflection detection. However, in this geometry, optical mammograms can already be obtained from raw data and reconstruction is not mandatory. Moreover, the thickness of the tissue in the slab-like geometry is typically between 4 cm and 8.5 cm, whereas for the freely pending breast the tissue thickness exceeds 10 cm close to the chest wall. Simulations have shown that the slab-like geometry offers the better detection sensitivity. 50 
Imaging of indocyanine green absorption
The first application of ICG for the detection of breast tumours in patients was performed by Ntziachristos et al. 51 In this investigation optical imaging was concurrently done with 
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Advances in Contrast-Enhanced NIR Diffuse Optical Imaging of Diseases Using ICG gadolinium-enhanced MR breast imaging. The breast of the patient lying in prone position in the MR scanner was slightly compressed between two parallel plates [cf. Figure 1(b) , detection by fibres]. Transmission of laser photons through the breast was investigated using a picosecond diode laser (wavelength 830 nm) and time-correlated single photon counting for detection. About 3 min after the ICG bolus transmission, data were recorded for a plane selected according to the location of the lesion in the MR images recorded a few minutes earlier. The ICG dose amounted to 0.25 mg kg −1 body weight which is in accordance with the range of values advised by ICG deliverers for clinical use in liver diagnostics. The authors investigated a 70-year-old patient with a 1 cm invasive ductal carcinoma, a patient with a benign lesion (1.5 cm fibro adenoma) and a healthy case. For both the malignant and the benign lesion, ICG induced absorption changes reconstructed by a perturbation approach revealed good congruence with the Gd-enhanced MR images, i.e. the diffuse optical tomography method was capable of localising both lesions in vivo.
Whereas Ntziachristos et al. 51 had measured the ICG absorption at a selected fixed time after the bolus, Intes et al. 52 observed the full time course of ICG uptake and wash-out for three breast lesions and the corresponding healthy tissue using a dose of 0.25 mg kg −1 body weight. Patients were investigated with a CW imager (wavelength 805 nm) with source and detector fibres arranged in a circle around the pending breast [cf. schematic set-up in Figure 1 (c)]. 52 The fibre holder was positioned in the plane of the tumour using the prior information about tumour location from palpation. Figure 2 shows the time courses of ICG concentration reconstructed by a perturbation approach. As can be seen, for the two malignant lesions (case I: adenocarcinoma, palpable size 2-3 cm; case II: invasive ductal carcinoma, size 3 cm × 4 cm) the inflow and the wash-out were significantly slower compared to the benign lesion (fibroadenoma) and to the examples of healthy tissue. Intes et al. 52 assumed that these differences were caused by structural and functional abnormalities of the vessels in the lesions such as chaotic vessel structure, excessive branching and blind vascular endings resulting in a locally increased resistance to blood flow. Furthermore, they discussed that extravasation of ICG could be appreciable in the malignant lesions. 52 Another possible reason could be that the large lesions already showed necrotic features, in accordance with results of Poellinger et al. 53 who observed a delayed inflow of ICG into a necrotic tumour.
Rinneberg et al. 54 had investigated 11 patients with suspicious lesions using an intravenously injected bolus of ICG with the same dose as Ntziachristos et al. 51 and Intes et al. 52 (0.25 mg kg −1 ). Measurements were performed in the slab-like compression geometry employing a time-domain scanning optical mammograph with a tandem configuration of source and detector fibre [cf. Figure 1 (a)]. 54 From optical mammograms of the suspicious breast recorded without ICG, a region of interest was defined containing the absorbing lesion and surrounding healthy tissue. Starting before ICG application this region was scanned repetitively for typically 10 min to study the time course of ICG absorption at 785 nm. Figure 3 shows an example of a patient with an invasive ductal carcinoma (size 2 cm). The carcinoma can clearly be recognised prior to application of ICG due to its increased intrinsic absorption at 670 nm [ Figure 3 (a)]. In Figure 3 (b), the corresponding map of total haemoglobin concentrations is plotted. Figure 3 (c) displays the time courses of ICG absorption for the carcinoma and two reference positions. Due to the increased vascularisation, the absorption change is highest at the location of the carcinoma. In Figure 3 normalised curves fall on top of each other indicating that the change in the absorption coefficient due to the wash-in and wash-out of the dye is proportional to the total haemoglobin concentration. Hence, an optical mammogram representing the absorption changes in the breast a few minutes after bolus injection essentially yields the same information as an optical mammogram without ICG displaying the haemoglobin concentration. This is a consequence of (i) the strong binding of the ICG molecules to plasma proteins and (ii) the negligible ICG extravasation for the applied dose. Moreover, the coincidence of the normalised curves in Figure 3 (d) shows that the pharmacokinetics of ICG in the tumour does not substantially differ from that of the healthy tissue. 54 
Fluorescence imaging of breast tumours
The detection of ICG in breast tissue using fluorescence offers the advantage that the signal does not have any significant background contribution, since tissue autofluorescence in the NIR spectral range is almost negligible. In contrast, the increase in absorption by ICG is superimposed onto the intrinsic tissue absorption due to haemoglobin, limiting the detection of weak ICG signals, which are present, in particular, at later times after injection. On the other hand, due to the low quantum yield of ICG, the intensity of fluorescence signals is much lower than the difference in the transmitted excitation signal used in absorption detection. The reduced scattering coefficients and the absorption coefficients for the fluorescence photons travelling through the tissue differ only slightly from those of the excitation photons and the diffusive nature of the imaging method remains unchanged. At higher dye concentrations, re-absorption of fluorescence photons by the dye could become significant. In time-resolved measurements the fluorescence lifetime causes an additional broadening of the detected fluorescence pulses, whereas in frequencydomain measurements, an additional phase shift is obtained compared to corresponding laser signals. Intrinsic absorbing and scattering tissue heterogeneities influence the measured fluorescence intensities in a similar manner as the intensities at the laser wavelength. Therefore, lesion contrast in fluorescence raw images can become negative despite a locally increased ICG concentration. If the increased number of emitted photons is just compensated for by the lesion absorption, fluorescence contrast could even be cancelled out. As will be discussed below, to visualise the lesion either reconstruction of the ICG concentration or an absorption correction method have been used. These schemes required the detection of the excitation laser signals together with the fluorescence signals.
First results on fluorescence measurements with ICG for the detection of breast cancer were published by Corlu et al. 55 in 2007. These investigations demonstrated that ICG fluorescence from breast tissue using an ICG bolus with a dose of 0.25 mg ICG per kg body weight can be detected in vivo with sufficient signal-to-noise ratio. Corlu et al. 55 employed a CW technique with CCD camera detection [ Figure 1 (b)]. The slightly compressed breast was suspended in a matching -49 - 
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Advances in Contrast-Enhanced NIR Diffuse Optical Imaging of Diseases Using ICG fluid to avoid over-exposure of the camera at the edges of the breast. The fluorescence measurement was started 6 min after bolus injection. Images of the ICG concentration were obtained by 3D reconstruction using the normalised Born approximation of the fluorescence diffusion equation. The intrinsic optical properties of the breast were derived from a frequency-domain measurement in reflection without ICG. Corlu et al. 55 investigated three patients with invasive ductal carcinomas. Figure 4 shows a representative example of the reconstructed data measured for a 54-year-old patient with a 1.6 cm × 1.3 cm × 1 cm lesion. The tumour is characterised by 25% contrast in the total haemoglobin concentration, by a slight deoxygenation of 9% and by a contrast in the scattering coefficient, µ s ¢, of 50%. The ICG concentration derived from the fluorescence data provides a much larger contrast of about 250%. Similarly, in the other two cases, contrast in ICG concentration was much larger than in haemoglobin concentration. Corlu et al. 55 explained this observation by accumulation of ICG due to leaky tumour vasculature. This result is different to that of Rinneberg et al., 54 although the same dose of ICG was applied. As discussed above, Rinneberg et al. 54 observed a similar lesion contrast for haemoglobin and ICG concentrations which means that extravasation was negligible in this study. Neither Intes et al. 52 nor Ntziachristos et al. 51 compared their measured results obtained using ICG to haemoglobin data. Generally, the almost complete binding of the dye molecules to plasma proteins, as accepted in the literature, should hinder fast extravasation of ICG.
In 2009 the first results of a clinical pilot study by Hagen et al. 56 were published, in which extravasation of ICG was explicitly exploited as a contrast mechanism to improve the differentiation between malignant and benign breast lesions. Hagen et al. 56 used a time-domain multichannel fluorescence mammograph to scan the slightly compressed breast [cf. Figure 1(a) ]. Details of the instrument can be found in Grosenick et al. 57 To correct for the heterogeneous tissue absorption, raw fluorescence data were normalised to laser transmission data at the excitation wavelength (780 nm) yielding fluorescence ratio images, which directly highlight regions of increased dye concentration. Instead of using a single bolus, investigations on patients were performed with a bolus followed by a constant infusion to ensure a constant ICG level in the blood vessels for a first fluorescence scan. At this time, ICG is contained mainly in the blood vessels. As can be seen in the example in Figure 5 (a), the corresponding fluorescence ratio mammogram shows the highly vascularised carcinoma as well as the other vessels in the breast. The same information is obtained from the laser transmission mammogram econstructed total hemoglobin concentration, blood oxygen saturation, reduced scattering at the excitation wavelength plotted in Figure 5 (b). Hence, the fluorescence measurement does not yield any essential improvement compared to the absorption measurement. Figure 5 (c) shows that the lesion contrast is even larger for a transmission measurement at 660 nm without contrast agent, i.e. the contrast agent does not really improve the detection of the carcinoma when used in this way. The situation changes dramatically when the fluorescence measurement is done about 30 min after stop of the infusion. At this time, ICG has been washed out from the blood by the liver and the small amount of extravasated ICG becomes visible. Figure 5(d) shows the resulting fluorescence ratio mammogram.
Here the carcinoma appears versus an almost homogeneous background. Hagen et al. 56 discussed the possibility that ICG bound to plasma proteins behaves like a macromolecular contrast agent which can extravasate in carcinomas due to a higher vessel permeability. After extravasation, the protein bound ICG hardly diffuses because of its large effective molecular weight and stays within the extracellular extravascular space, in accordance with the enhanced permeability and retention effect of macromolecules in cancer. 58 Investigations on 20 patients with suspicious lesions have confirmed this general picture. 53 Furthermore, benign lesions such as fibroadenomas and fibrocystic diseases did not show fluorescence contrast at the late time of measurement. Obviously, the capillaries in the benign lesions were not permeable for the ICG-labelled macromolecules. Hence, the clinical study showed a potential method to differentiate malignant from benign lesions. 53 A more advanced data analysis could probably yield quantitative information about permeabilities similar to methods in MR imaging. 59 Generally, due to the combination of bolus and infusion, the total ICG dose in the present study was larger by a factor of 3 to 4 compared to the above discussed investigations. This dose, together with the elongated ICG circulation time, resulted in an amount of extravasated ICG which could be detected with high signal-tonoise ratio. Finally, it is remarkable that Hagen et al. 56 could observe ICG fluorescence, even 24 h after dye injection which shows the long retention time of extravasated ICG.
Apart from ICG, there is only one other dye which has been applied to detect breast cancer in humans so far. This dye, called omocyanine (Bayer Schering Pharma, Berlin, Germany), also known as TSC (tetrasulfonated carbocyanine dye), is a non-specific ICG derivative with a slightly shorter fluorescence wavelength (about 780 nm) than ICG. 15 It has a higher quantum yield and does not show the high binding affinity of ICG to plasma proteins. Hence, it should act as a small molecule which can easily extravasate. Van de Ven et al. 18 used omo cyanine in a dose finding study on 11 patients. Measurements were performed with a tomographic fluorescence mammograph using a CW laser source with a wavelength of 730 nm. During investigation the patient lies in the prone position with the breast suspended in a cup-like chamber filled with a scattering matching fluid [cf. Figure  1(d) ]. Three-dimensional reconstruction of fluorescence and absorption images has been performed by perturbation approaches assuming constant scattering properties throughout the breast. Compared to ICG, omocyanine circulates for a much longer time in the blood. Therefore, patients were investigated several times up to 24 h after bolus injection. The highest lesion contrast was obtained about 8 h after bolus injection. As well as the lesions, glandular tissue showed enhancement of the small dye molecules starting 30 min after -51 - 
210
Advances in Contrast-Enhanced NIR Diffuse Optical Imaging of Diseases Using ICG injection and still being evident 24 h later. Furthermore, the nipple was visible with high intensity. Although very preliminary, these results indicate several problems in the distinction of lesions from healthy tissue when applying omocyanine. Recently, Poellinger et al. 19 reported on a multicentre dose finding study with omocyanine in which 52 patients with malignant or benign breast lesions were included. These investigations were performed with a prototype CW fluorescence tomograph (Computed Tomography Laser Mammography, Imaging Diagnostic Systems, Inc., Ft Lauderdale, FL, USA). Fluorescence and absorption images of the freely pending breast were obtained by using a circular source-detector arrangement [cf. Figure 1(c) ] which could be shifted from the chest wall to the nipple plane. For a dose of 0.1 mg kg −1 , a detection rate of 100% was found for malignant lesions. The rate was about 71% when employing the absorption mode of the device. Poellinger et al. 19 observed considerable variations in the sensitivity at different omocyanine concentrations and concluded the need of further investigations to assess the suitable dose for breast imaging. Moreover, a large number of additional lesions was observed, both in the fluorescence and absorption images, indicating a low specificity.
Hence, both studies with omocyanine also revealed dye enrichment in healthy tissue regions, whereas ICG enrichment was restricted to malignant lesions possibly due to its macromolecule-like extravasation behaviour. Generally, this macromolecular feature is an advantage over MR breast imaging with Gd chelates, since the Gd complex acts as a small molecule. Differentiation between different types of lesions is mainly derived from the speed of uptake of the contrast agent, with only moderate success. To improve this situation, the development of Gd-based macromolecular contrast agents is pursued, for example, by covalently binding Gd to albumin. 60, 61 This research is in the phase of small-animal imaging so far. The optical contrast agent ICG has this macromolecular feature intrinsically, due to its high binding to plasma proteins. This agent is approved for intravenous injection and is well tolerated. Together with the existing methods for fluorescence imaging in breast tissue, ICG could offer a new way to improve specificity in breast cancer detection.
Optical imaging of perfusion in the human brain

Non-invasive monitoring of brain perfusion
Magnetic resonance imaging (MRI) can be considered the "gold standard" in the diagnosis of acute stroke. 62 In particular, by applying a bolus of Gd-DTPA, perfusion-weighted MR imaging allows cerebral blood flow (CBF) to be determined. However, this technique, as well as other imaging modalities such as positron emission tomography (PET) or computed tomography (CT), requires the patient to be transported to the imaging facility. These methods cannot be applied at the bedside for continuous monitoring of patients during the subacute phase of stroke. Similarly, the techniques are not suited to monitoring blood flow in the brain during cardiac surgical interventions. Other tracer techniques such as 133 Xe dilution require application of radioisotopes. 63 Transcranial Doppler sonography, which can be used at the bedside, measures blood velocity in cerebral arteries instead of CBF in the microvasculature. 64 In general, NIR optical imaging combined with an intravenously injected bolus of ICG offers a way to quasi-continuously monitor brain perfusion. Due to the size of the adult head, optical measurements on the brain are restricted to the reflection geometry. As illustrated in Figure 6 , a source and a detector optical fibre are positioned over a certain area of the brain. Absorption changes by an ICG bolus (or related fluorescence) are sampled by the photon trajectories between both fibres that pass skin and skull and may reach the brain. In general, the intravenously applied dye bolus appears not only in the brain, but also in extracerebral layers. Both deep and superficial compartments contribute to the signal. Two major strategies are available to suppress the influence of superficial signals. By increasing the source-detector distance, deeper tissue regions become accessible and contribute to the signal with larger weight, at the cost of reduced total signal intensity. Alternatively, one can use the time-of-flight of detected photons to distinguish signal contributions from upper and lower layers ( Figure 6 ), since only photons with sufficiently long times of flight have a chance to travel through deeper tissue.
Estimation of cerebral haemodynamics from ICG bolus measurements was first investigated in animal studies. Colacino et al. 65 injected ICG into the common carotid artery of ducks and derived CBF from the mean transit time determined from the ICG clearance curve. Ferrari et al. 66 used ICG to study effects of haemorrhagic hypotension on CBF in dogs. As shown by Kuebler et al. 67 in ICG bolus tracking experiments on piglets, a blood flow index (BFI) can be used as a measure of CBF. This index is defined as the ratio of the maximum change in cerebral ICG concentration and the corresponding rise time. It is used to assess the broadening of the bolus due to reduced perfusion in the tissue volume under investigation. Moreover, often a delayed arrival of the bolus is observed, in particular when an impaired region of the brain is supplied from the contralateral side by collateral arteries via a prolonged route. Based on these characteristics of bolus shape and delay, brain perfusion in patients suffering from unilateral ischaemic stroke can be assessed relatively by comparing measurements on both hemispheres. This is possible even if the arterial input function, i.e. the bolus shape at the entrance to the tissue under investigation, is not known.
It should be noted that, recently, another optical method, diffuse correlation spectroscopy (DCS), has been applied to image perfusion of the human brain. 11 A study by Diop et al. 68 compared DCS with time-resolved optical bolus tracking in piglets, thereby opening up a chance for absolute calibration of the flow measured by DCS. The DCS method, still suffering from signal-to-noise problems and issues in theoretical modelling, could potentially measure cerebral blood flow without the need to inject a contrast agent.
Absorption detection of indocyanine green bolus
Gora et al. 69 and Keller et al. 70 discussed methods to derive CBF from ICG bolus tracking measurements based on CW light detection. Furthermore, Keller et al. 70 showed the correlation between CBF derived from optical measurements and results from perfusion-weighted MR imaging. To distinguish absorption changes in the intracerebral compartment from those in the extracerebral tissue, Kohl-Bareis et al. 71 applied frequency-domain NIR reflectometry using intensitymodulated light. From measured phase shifts, the mean timeof-flight of the detected photons was derived. The authors found that this quantity was more sensitive to absorption changes in the cerebral compartment than light attenuation. Using a commercial CW NIR spectrometer (NIRO 300; Hamamatsu Photonics K.K., Japan) to investigate 13 patients suffering from stroke, Terborg et al. 72 observed a delay of bolus arrival for the diseased hemisphere of the brain of about 5 s on average, whereas no differences were observed between the two hemispheres for the control group. In this study, the interoptode distance was 4-5 cm. The ICG dose amounted to either 0.1 mg kg −1 or 0.5 mg kg −1 body weight. The authors discussed that the influence of the superficial layers on their results should be small, despite employing a CW technique, since the first part of the measured bolus time courses was used for analysis. This first part should mainly represent CBF, whereas the contribution from the skin was expected to be delayed in time, according to observations reported by Steinbrink et al. 73 and by Kohl-Bareis et al. 71 Liebert et al. 74 reported an improvement in depth sensitivity by employing a time-domain technique to record distributions of times-of-flight (DToFs) of photons travelling through the tissue. Measurements were performed for two sourcedetector combinations with an interoptode distance of 3 cm on both hemispheres of the brain. The investigations comprised application of three consecutive boluses of 5 mg ICG with a repetition time interval of 5 min to allow for substantial washout. From the DToFs, the CW attenuation, the mean timeof-flight and the variance were derived. In earlier studies on phantoms, it was already shown that these quantities are preferentially sensitive to absorption changes in different depths of a layered medium: attenuation is most sensitive close to the surface and less sensitive to cerebral changes, mean time-offlight extends sensitivity slightly into the volume and variance has its maximum sensitivity at even larger depths. 75 Changes in these quantities are assumed to be proportional to changes in absorption within the sampled volumes. 71, 73, 75 By investigating two healthy volunteers and two patients with stroke, Liebert et al. 74 confirmed these results in vivo. As an example, results for the two healthy subjects are displayed in Figure 7 . The time courses show that the bolus arrival appeared earlier in the variance than in the attenuation signal. Furthermore, at all four detector positions, the same times of bolus arrival were observed, whereas attenuation data showed some dispersion of arrival times. These results are in accordance with the expected earlier arrival of the bolus in the brain compared to the skin and to an inhomogeneous skin blood flow depending on temperature, compression and local vessel anatomy. 74 For the second subject in Figure 7 the mean times of flight also show a temporal dispersion for the different detectors which was interpreted as superposition of signal contributions from both the superficial and the brain tissue. 74 For the two patients investigated in this study, the delays between the diseased and the healthy hemisphere of the brain were clearly visible in the variance signals. In the case of the first patient with clinically confirmed acute cerebral ischaemia, a difference of about 10 s was measured. For the second patient with a complete occlusion of the right internal carotid artery, a 5 s delay of bolus arrival was observed. In both cases, delays between the hemispheres were much less pronounced in attenuation and mean timeof-flight, indicating the advantage of the variance of DToFs for brain imaging. 74 Steinkellner et al. 76 employed the time-resolved method of ICG bolus tracking in a clinical study on 10 patients suffering from acute ischaemic stroke with affection of the middle cerebral artery territory. In this study, four source-detector combinations with an interoptode distance of 3 cm were used on each hemisphere of the patient's brain. Up to four bolus injections at a repetition time of 5 min were performed in each patient with a single bolus dose of 6 mg. In contrast to Liebert et al., 74 Steinkellner et al. 76 used spectral filters to block ICG fluorescence from detection. Absorption measurements on a healthy volunteer had shown that variance signals may be strongly influenced by fluorescence whereas CW attenuation is almost unaffected. This finding results from the considerably later appearance of the fluorescence maximum in comparison to the maximum of diffuse reflectance together with the strong weighting of late photons by the quadratic time dependence in variance. 76 Investigations of the 10 patients were carried out within the first day after onset of symptoms. Variance data revealed a clear delay of the bolus in the diseased hemisphere for all patients, with delay times ranging between 0.2 s and 5 s. These data were averages over the four source-detector combinations. In a few cases, significant differences could be detected between the source-detector combinations, allowing the authors to roughly localise the diseased region in the brain. To compare the variance analysis with a CW measurement, Steinkellner et al. 76 derived the bolus delays from the time courses of the CW attenuation, too. From these data, the expected bolus delay in the diseased hemisphere was observed in only six of the 10 patients. These results underpin the limited value of CW data in assessing perfusion in the brain. Furthermore, Steinkellner et al. 76 found the variance to be less sensitive to motion artifacts than the CW attenuation.
Terborg et al. 77 performed a similar clinical study on 11 patients with infarction in the territory of the left or right middle cerebral artery. As in their first study, 72 a CW NIR instrument was used (NIRO 300; Hamamatsu) with an interoptode distance of 4 cm to 5 cm. The mean ICG dosage amounted to 0.1 mg kg −1 body weight. Despite the limited sensitivity of CW attenuation to absorption changes in the cortex, found in the above discussed investigations, 71, 74, 76 Terborg et al. 77 observed a significant difference between bolus arrival in the diseased and the unaffected hemisphere. Moreover, the authors found a close correlation of the interhemispheric bolus delay between NIR measurements with ICG and perfusion-weighted MRI with Gd-DTPA.
Monitoring of cerebral perfusion by ICG bolus tracking has also been used during cardiac surgery to check for sufficient blood supply by cardiopulmonary bypass. In 1993, Roberts et al. 78 reported on investigations on children with a bolus dose of 0.1 mg kg −1 employing a commercial CW NIR spectrometer (NIRO 500; Hamamatsu) for detection of the absorption changes. The authors quantified cerebral blood flow by relating the changes in cerebral ICG concentration to the arterial ICG concentration which was measured invasively by a fibre-optic dye dilution catheter. 78, 79 As in the case of stroke monitoring, CW measurements of ICG absorption during cardiac surgery should be affected by the dye in the extracerebral tissue. Since intracerebral and extracerebral blood vessels are expected to respond both, but differently, to cardiotechnical and pharmacological -53 - Dátñ, mean time-of-flight; and DV, variance) for two healthy subjects observed after administration of an ICG bolus. 74 Results are plotted for two locations on the left (blue and grey lines) and two locations of the right hemisphere (red and orange lines). Note that in subject 1 the cerebral (i.e. simultaneous) bolus arrival is detected in Dátñ and DV, whereas in subject 2, a simultaneous bolus arrival in both hemispheres is only seen in DV. Reprinted with permission of Elsevier from Liebert et al. 74 A colour version of this figure is available on the web.
interventions, 80 a good selectivity for intracerebral tissue is essential. Therefore, Steinbrink et al. 80 employed a frequency-domain technique similar to the approach of Kohl-Bahreis et al. 71 mentioned above. By analysing changes in the phase signal, they increased the depth of the sampled volume towards the cerebral tissue, whereas the CW intensity was used as a measure for the extracerebral compartments. Investigations were performed on four patients undergoing heart surgery with cardiopulmonary bypass before, during and after the surgery. Measurements were done on the forehead using two to five injections of 5 mg ICG boluses. The investigations revealed clear differences between intracerebral and extra cerebral tracer kinetics with a distinct delay of the extracerebral bolus arrival. Furthermore, by comparing the blood flow index of the intracerebral tissue (derived from phase data) after surgery with the corresponding value before surgery, a significant increase was observed for all patients. In contrast, blood flow indices derived from CW intensities did not show significant alterations after surgery. Steinbrink et al. 80 concluded, that CW bolus tracking does not seem to be well suited to characterise cerebral blood flow due to the interference from superficial layers.
Schytz et al. 81 tried to compare the blood flow index (BFI) accessible by ICG bolus tracking to cerebral blood flow (CBF) obtained from 133 Xe single photon emission computer tomography ( 133 Xe-SPECT). To this end, 10 healthy subjects were investigated with a bolus of acetazolamide. This drug is known to cause a temporary increase in cerebral blood flow by dilatation of arterioles. 82 ICG kinetics was monitored by a CW NIR device (NIRS2; TechEn Inc., USA) at the forehead using source-detector distances of 1 cm and 3 cm. 81 In two cases, distances from 3 cm to 5 cm were chosen. In the SPECT data, an increase in CBF up to about 50% was observed. In contrast, BFI derived from the optical measurements did not show any significant increase, similar to a previous attempt to detect the effect of acetazolamide by Tachtsidis et al. 83 Since Schytz et al. 81 could see a shift of the bolus arrival to shorter times for increased source-detector distance, they concluded that measurements with the larger distances should give access to the cerebral tissue. The authors discussed that the changes in blood flow could have possibly been masked by changes in the cerebral as well as in the skin blood volume, or by differences in arterial concentration after each ICG bolus administration.
As well as non-invasive ICG bolus tracking, there have been attempts to develop NIR spectroscopy of the brain in connection with conventional invasive probes routinely used in neurosurgical interventions. Recently, Keller et al. 84 equipped a probe for intracranial pressure monitoring with optical fibres for NIR spectroscopy. This arrangement was successfully applied to a patient to determine CBF by ICG bolus tracking. Although application of this approach is limited to patients for whom an invasive intervention is advised, the technique should permit study of the true CBF without extracerebral interference and lead to a better understanding of the benefits and limits of the non-invasive transcranial measurements.
Fluorescence detection of indocyanine green bolus
The methods for assessing brain perfusion discussed so far were all based on absorption measurements. In 2006 it was shown by Liebert et al. 85 that the bolus passage in the brain can also be detected by fluorescence measurements. Investigations were performed with a time-domain set-up. To compensate, in part, for the low fluorescence signal caused by the low quantum yield of ICG, Liebert et al. 85 used a picosecond diode laser (wavelength 780 nm) together with an optical amplifier. With this arrangement, the average light power was greater by a factor of about 10 compared to the absorption measurements discussed above. To reduce power density on the skin, the excitation spot was enlarged to about 6 mm diameter. Measurements were performed on two healthy subjects with the source and the detector optode placed 3 cm apart over the left hemisphere. Fluorescence photons and reflected laser photons were detected simultaneously. From the measured distributions of times of arrival of fluorescence photons, the authors calculated CW fluorescence, the mean time-of-flight and the variance. Prior to injection of the dye there is no ICG fluorescence signal present, i.e. times of flight and variance at the fluorescence wavelength are undetermined. Therefore, Liebert et al. 85 administered a small amount of dye (1 mg) just a few minutes before injection of the main bolus (11 mg), and baseline data could be determined for all quantities of interest. As an example for the observed time courses, Figure 8 shows results for two independent bolus applications on the first subject. 85 The results found at the excitation wavelength corresponded to the results of the previous investigation by Liebert et al. 74 discussed above (cf. Figure 7) . At the fluorescence wavelength, the CW intensity rises during the bolus, since the inflow of the dye increases the number of fluorescence photons. The time course for the first moment of the fluorescence distributions of times of arrival shows an increase during inflow of the bolus followed by a pronounced decrease below the baseline value. Similar behaviour was observed in the first bolus application for the variance data [ Figure 8 (e)], whereas in the second, more noisy, data set only the decrease became visible [ Figure 8 (f)]. These results were confirmed by the investigations on the second subject. Monte Carlo simulations have shown that the initial increase in fluorescence mean time-of-flight and variance is connected to the early inflow of the bolus into the intracerebral tissue. 85, 86 When the bolus has not yet arrived in the extracerebral tissue, all detected fluorescence photons must have been emitted from the deeper tissue, apart from the small baseline contribution. Accordingly, the detected fluorescence photons have a prolonged time-of-flight compared to the baseline. The long travel times of the fluorescence photons also increase the variance. A few seconds later, when the bolus has reached the extracerebral tissue, fluorescence photons from the nearsurface regions with shorter times of flight strongly contribute to the fluorescence signal and both mean time-of-flight and variance decrease. Having the biphasic time courses in mind, Liebert et al. 85, 86 concluded that monitoring fluorescence instead of diffusely reflected laser photons may be advantageous for the assessment of cerebral perfusion. However, this method has not been applied in clinical studies so far. On the other hand, the ICG fluorescence measurements have demonstrated that moderate dye concentrations can be detected in the brain by recording fluorescence. This result suggests that other fluorescent probes may be detectable, in particular probes for molecular imaging of diseases in the brain. 87 In conclusion, the various studies on ICG bolus tracking for the assessment of brain perfusion have shown promising results. The optical methodology has the potential to be developed as a bedside monitoring tool which can be applied in intensive care units. Here, a sequence of ICG-based perfusion measurements could complement initial MRI investigations on patients with subacute stroke. An obstacle of the optical technique is the limited depth sensitivity. Sub-cortical stroke regions are not accessible, even when using the time-resolved technique.
Fluorescence imaging of rheumatoid arthritis
Recently, contrast-enhanced optical imaging with ICG was proposed as a method to improve early detection of rheumatoid arthritis in finger joints. 88, 89 In general, rheumatoid arthritis, which irreversibly degrades joints, cannot be cured with the presently known methods of therapy. Medical treatment can only delay or stop the progression of the disease. 90 Therefore, early diagnosis of rheumatoid arthritis is of great importance. However, conventional radiography as the most common imaging method is not suited for early disease assessment. 91 So far, contrast-enhanced MRI and ultrasound have been investigated as alternatives. [91] [92] [93] [94] In the past, optical imaging ig. 8 ormalized changes of moments of distributions of times of arrival of fluorescence photons black lines) and distributions of times of flight of diffusely reflected laser photons (gray ines) for a healthy subject during two sessions of ICG bolus administration. 85 of finger joints in humans was focused on the detection of intrinsic differences in the scattering and absorption properties of the tissue, with limited success only. 12, 13 Fluorescence imaging of joints was mainly used as a tool to characterise the distribution of newly developed specific probes for rheumatoid arthritis in small animal models. 95, 96 However, as well as molecular features, the perfusion of the joints can be considered as a contrast mechanism to detect the disease. As discussed in the preceding sections, ICG is an ideal drug to study perfusion in humans by bolus tracking.
So far, all studies of rheumatoid arthritis in humans with ICG were based on the detection of fluorescence 88, 89, [97] [98] [99] rather than absorption changes during bolus passage. Figure 9 illustrates the basic features of the measurement set-ups. A continuous-wave excitation light source is used to homogeneously illuminate the surface of one or both hands. Fluorescence radiation, originating from ICG after intravenous bolus injection, is detected in reflection geometry by a sensitive CCD camera equipped with appropriate spectral filters to block the excitation light reflected or remitted by the tissue. Images are recorded for a time period of typically 10-15 min to measure the inflow and the wash-out of the dye. The uniform illumination of the whole hand can be understood as superposition of light from homogeneously distributed point-like sources. As long as a fluorescent object in the tissue is not shadowed by locally increased absorption or scattering, it is most effectively excited by the sources situated directly above its position. Accordingly, the CCD pixel representing the detector position above the object receives the largest fluorescence intensity from this object. Since tissue autofluorescence is negligible for the excitation wavelength used, fluorescent objects can be detected, even from larger depths, provided that a sufficient number of emitted photons reaches the detector. Generally, the detection of deeper situated fluorescent objects is hampered by more superficial ones.
In the first exploratory study by Fischer et al., 89 one hand of each subject was investigated. Measurements were performed with nanosecond laser pulses at a wavelength of 740 nm generated by a pulsed Nd:YAG laser system equipped with an optical parametric oscillator at a repetition rate of 100 Hz. Illumination of the hand with an average power of 2 mW cm −2 was realised via a fibre with a diffusing ball at the end which was located in a reflector. Fluorescence was detected by an intensified CCD camera, which was gated with respect to the excitation pulses to suppress the influence of ambient light. An ICG bolus with a dose of 0.1 mg kg −1 body weight was used. In this study, five healthy volunteers, four patients with rheumatoid arthritis and one patient with psoriatic arthritis were investigated prospectively. Figure 10 shows typical fluorescence images at selected times after dye injection. For the healthy volunteers, fluorescence always appeared first in the fingertips. Furthermore, during ICG wash-out from the blood, fluorescence intensity in the joints was observed to be slightly less than in the finger tip. For the patients, two different patterns were found. One group of joints showed a fast and strong increase in fluorescence intensity (see the example in Figure 10 ). In the other group, such a rapid increase was not present, i.e. fluorescence appeared first at the finger tips as in the healthy cases. However, for all patients, the fluorescence intensity at later times was larger in inflamed joints than in the corresponding finger tips. Disease classification by optical imaging showed good correlation with clinical findings and with data from contrast-enhanced MRI. 89 In a later study by Dziekan et al. 98 with a second generation set-up, both hands were illuminated simultaneously using light emitting diode arrays instead of a pulsed laser source. Furthermore, the intensified CCD camera was replaced by a more robust electron multiplying CCD (EMCCD) camera, and the whole set-up was covered by a dark box to block ambient light. The hands were placed onto a preformed support to avoid movement artefacts. Data were recorded for 12 volunteers and 16 patients with rheumatoid arthritis. The differentiation between healthy and diseased joints in the study by Fischer et al. 89 was based on a normalisation procedure under the assumption that the finger tips are not inflamed. In the subsequent prospective study, Dziekan et al. 98 developed an advanced data analysis algorithm based on correlation functions of the time courses of fluorescence intensities of the particular joint and the corresponding finger tip. The variances of these correlation functions were normalised to the variance of the autocorrelation function at the finger tip to eliminate the influence of bolus shape and liver uptake effects. For diseased joints, the normalised variance was found to be larger than for the healthy joints. 98 In other words, for the diseased joints, the observed time courses of ICG bolus passages were broadened to a larger extent than for the healthy joints.
Meanwhile, a larger clinical study is in progress with commercial devices (Xiralite; Mivenion GmbH, Germany) which are based on the set-up used by Dziekan et al. 98 Bremer et al. 97 reported that the technique seems to be capable of differentiating active synovitis from other diseases -55 - such as chronic osteoarthritis, since only the first disease shows contrast enhancement due to neoangiogenesis. Recently, first results on ICG based fluorescence imaging were reported for investigations on children with juvenile arthritis. 99 Generally, the discussed investigations underline the high potential of fluorescence imaging of joints with ICG bolus tracking.
Conclusions
Contrast-enhanced clinical investigations using ICG are broadly established worldwide, mostly for fundus angiography in the eye, for imaging of microcirculation in plastic and reconstructive surgery and for transplanted vascularised flaps. The examples discussed in this review show that contrast-enhanced optical imaging with ICG has found several new applications in diffuse optical imaging on humans during the last years. Since ICG absorbs and fluoresces in the near-infrared spectral region, it can be detected through several centimeters of highly scattering tissue in vivo. The strong binding of ICG to plasma proteins is an ideal property to use the agent as a tracer for the investigation of perfusion in stroke monitoring or in the detection of arthritis. Furthermore, the binding properties of ICG are responsible for its macromolecular-like extravasation behaviour, which might offer the possibility to differentiate malignant from benign breast lesions. Extravasation of ICG could also be of interest in the detection of rheumatoid arthritis.
The fast wash-out of ICG from the blood limits the amount of extravasated dye due to the short interaction time. On the other hand, since the extravasated dye can be optimally detected after wash-out from the blood, corresponding measurements on patients are possible within, typically, 1 h after dye injection. Furthermore, the fast wash-out allows for repeated investigations without significant waiting times which is of interest, in particular, for stroke monitoring. The low fluorescence quantum yield of ICG did not appear as a general limitation in diffuse optical imaging. To a large extent, the reported applications were based on absorption rather than fluorescence detection and, in the case of fluorescence measurements, experimental techniques with sufficient sensitivity were available.
So far, most of the discussed investigations of contrastenhanced diffuse optical imaging with ICG have been based on a limited number of patients, and further clinical studies are required to fully evaluate the potential of this method. Finally, it is worth noting that fluorescence imaging with ICG contributes to the development of new measurement techniques which are, in turn, a prerequisite for future applications of molecular probes in optical imaging of diffusely scattering tissue.
